Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95

Audrey Simon (1) , Peoc'H Michel (2) , Philippe Casassus (3) , Eric Deconinck (4) , P Colombat (5) , Bernard Desablens (6) , Olivier Tournilhac (7) , Houchingue Eghbali (8) , Ch Foussard (9) , Jerome Jaubert (10) , Jean-Pierre Vilque (11) , Jean François Rossi (12) , Virginie Lucas (13) , V Delwail (14) , Antoine Thyss (15) , Frederic Moloisel (16) , Noel Milpied (17) , Steven Le Gouill (18) , Thierry Lamy (19) , R Gressin (20)

1 Hematology
2 antomie pathologique
3 Service d'hématologie clinique [Avicenne]
4 Haematology
5 Service d'hématologie [Tours]
6 Laboratoire d'Hématologie [CHU Amiens]
7 Clinical Haematology
8 Hematologie
9 Haematology
10 Hematology
11 URCA - Université de Reims Champagne-Ardenne
12 Haematology
13 Oncology
14 Haematology
15 Haematology
16 Haematology
17 Haematology
18 Service d'hématologie clinique
19 Haematology
20 Hematology

Peripheral T-Cell lymphomas (PTCL) are relatively rare diseases but appear as highly aggressive and display worse remission and survival rates than B-cell lymphomas. Despite non satisfactory results with the CHOP regimen, it remains the reference front line therapy in these diseases, but has not been challenged in phase III trials. The GOELAMS group devised an alternative therapeutic schedule including Etoposide, Ifosfamide, Cisplatin alternating with Doxorubicin, Bleomycin, Vinblastin, Dacarbazine (VIP-reinforced-ABVD) and compared it to CHOP/21 as front-line treatment in non cutaneous PTCL. All newly diagnosed patients were eligible. The primary objective was to improve the 2-years event-free survival (EFS) rate. Secondary objectives were to compare the response rates, overall survival, and toxicities as well as identify prognostic factors. 88 patients were identified between 1996 and 2002. Both arms were well balanced for patients' characteristics in terms of histological and clinical presentation. No significant difference was observed between the two arms in terms of 2-years EFS. ALCL type and Ann Arbor stage I-II were identified as two independent favourable prognostic factors influencing survival. The VIP-rABVD regimen was not superior to CHOP/21 in term of EFS as first-line treatment of PTCL, confirming that CHOP/21 remains the reference arm in these lymphomas.

Mots clés: Medicine

Audrey Simon, Peoc'H Michel, Philippe Casassus, Eric Deconinck, P Colombat, et al.. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. British Journal of Haematology, 2010, 151 (2), pp.159. ⟨10.1111/j.1365-2141.2010.08329.x⟩. ⟨hal-00569409⟩